Biotech companies in the United States by operating margin
Operating income as a share of revenue for the latest fiscal year: what the business keeps of each dollar of sales before interest and tax. Banks, insurers and other companies that report no operating income are not ranked.
Krystal Biotech leads the 14 biotech companies in the United States ranked by operating margin, at 41.5%, ahead of Exelixis (37.6%) and Gilead Sciences (34.0%). Figures as of 19 Nov 2026, 20:53 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 14
- First
- Krystal Biotech41.5%
- Median
- 14.1%
- Combined market value
- AED 2.71T
- Countries
- 1
- Not ranked
- 6no operating margin on file
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Operating margin ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Krystal BiotechKRYS · Health Care | 41.5% | AED 34.4B | AED 1,160.86 | 0.23% up | 54% up | ||
| 2 | ExelixisEXEL · Health Care | 37.6% | AED 59.2B | AED 242.42 | 3.35% down | 63% up | ||
| 3 | Gilead SciencesGILD · Health Care | 34.0% | AED 761B | AED 613.58 | 1.14% down | 35% up | ||
| 4 | Halozyme TherapeuticsHALO · Health Care | 33.6% | AED 38.9B | AED 341.57 | 2.92% down | 39% up | ||
| 5 | AmgenAMGN · Health Care | 24.7% | AED 874.3B | AED 1,616.40 | 0.85% down | 32% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | 21.6% | AED 58.3B | AED 576.10 | 3.69% down | 17% up | ||
| 7 | Bio-TechneTECH · Health Care | 20.7% | AED 41.9B | AED 267.03 | 0.06% down | 24% up | ||
| 8 | RepligenRGEN · Health Care | 7.47% | AED 40.2B | AED 628.10 | 0.96% down | 12% up | ||
| 9 | Adaptive BiotechnologiesADPT · Health Care | -20.6% | AED 16.7B | AED 102.99 | 1.48% down | 74% up | ||
| 10 | Twist BioscienceTWST · Health Care | -36.2% | AED 28.3B | AED 415.43 | 2.78% down | 346% up | ||
| 11 | ModernaMRNA · Health Care | -158% | AED 298.3B | AED 737.13 | 1.99% up | 780% up | ||
| 12 | ImmunityBioIBRX · Health Care | -226% | AED 25.8B | AED 24.30 | 1.27% down | 232% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | -891% | AED 37.6B | AED 440.75 | 0.93% down | 87% up | ||
| 14 | CG OncologyCGON · Health Care | -4722% | AED 27B | AED 302.05 | 2.80% up | 97% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Operating margin is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Banks and insurers report no operating income and are not ranked on it. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED). 6 companies have no operating margin on file and are not ranked here.
Questions and answers
Which biotech companies in the United States rank first by operating margin?
Krystal Biotech (41.5%), Exelixis (37.6%) and Gilead Sciences (34.0%) are the top three of the 14 biotech companies in the United States ranked by operating margin as of 19 Nov 2026, 20:53 UTC.
How many biotech companies in the United States are in this ranking?
14 are ranked by operating margin. 6 more have no operating margin on file and are left out rather than ranked at zero.
What are these biotech companies in the United States worth together?
The 14 biotech companies in the United States ranked by operating margin have a combined market value of AED 2.71T as of 19 Nov 2026, 20:53 UTC.
What does ranking by operating margin measure?
Operating income as a share of revenue for the latest fiscal year: what the business keeps of each dollar of sales before interest and tax. Banks, insurers and other companies that report no operating income are not ranked.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Biotech companies in the United States by operating margin”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=operating-margin
Underlying data: Yahoo Finance; SEC EDGAR.